News & Events

Most Recent 2020 2019 2018 2017 2016 2015 2014 2013 2012

01.07.2021

Ribometrix Announces Collaboration with Genentech to Discover and...

12.15.2020

BioAtla Announces Pricing of Initial Public Offering

12.10.2020

4D Molecular Therapeutics Announces Upsized Pricing of Initial Pu...

12.09.2020

Reneo Pharmaceuticals Raises $95 Million in Series B Financing, C...

11.30.2020

Mirum Pharmaceuticals Announces European Medicines Agency Validat...

11.05.2020

VelosBio to be Acquired by Merck for $2.75 billion

10.22.2020

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-10...

09.10.2020

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug ...

08.19.2020

4D Molecular Therapeutics Announces First Patient Dosed in Phase ...

08.17.2020

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV ...

07.30.2020

Cyclerion Therapeutics Completes $24 Million Private Placement

07.15.2020

BioAtla Raises $72.5 Million In Series D Financing

07.08.2020

VelosBio Raises $137 Million in Series B Financing

06.16.2020

4D Molecular Therapeutics Raises $75 Million in Series C Financing

05.19.2020

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financin...

05.19.2020

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, ...

05.01.2020

HealthpointCapital Acquires Majority Stake in IlluminOss Medical,...

04.02.2020

Curzion Pharmaceuticals Acquired by Horizon Therapeutics

01.27.2020

Liquidia Submits New Drug Application for LIQ861 (treprostinil) i...

12.16.2019

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with F...

10.23.2019

Allievex Completes Series A Financing Led by Pappas Capital and N...

10.11.2019

Former CoLucid Drug, Lasmiditan, Receives FDA Approval

09.30.2019

Vertex and Ribometrix Establish Strategic Collaboration to Discov...

09.27.2019

Ribometrix Announces $7.8 Million in New Funding to Advance RNA-T...

09.16.2019

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Vir...

09.16.2019

Amplyx Pharmaceuticals Announces Positive Preliminary Data from O...

09.11.2019

Alex Arfaei Joins Pappas Capital As Partner

09.09.2019

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for Fosman...

07.17.2019

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

07.16.2019

Pappas Capital Expands Leadership Team With Appointments Of Kyle ...

05.20.2019

Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics ...

05.09.2019

Milestone Pharmaceuticals Announces Pricing of Upsized Initial Pu...

02.28.2019

IlluminOss Medical Launches the IlluminOss® Bone Stabilization Sy...

01.07.2019

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data...

11.13.2018

Ribometrix Announces $30 Million Series A Funding to Advance Pipe...

11.07.2018

Mirum Pharmaceuticals Secures $120 Million in Series A Financing

10.25.2018

Milestone Pharmaceuticals Announces $80 Million Private Financing

10.17.2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing

10.01.2018

VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Cl...

09.05.2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

08.08.2018

Milestone Pharmaceuticals Announces First Patient Randomized in t...

07.25.2018

Liquidia Technologies Announces Pricing of Initial Public Offering

06.20.2018

Kezar Life Sciences Announces Pricing of Initial Public Offering

04.25.2018

FDA Grants Fast Track Designation for OrphoMed’s ORP-101 fo...

04.10.2018

Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner

03.19.2018

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectiou...

01.10.2018

IlluminOss Medical Granted FDA Marketing Clearance for the Illumi...

01.03.2018

Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients w...

12.06.2017

Pappas Capital Portfolio Company Rotation Medical Acquired by Smi...

12.06.2017

Smith & Nephew Completes Acquisition of Rotation Medical Inc.

10.23.2017

Smith & Nephew Acquires Tissue Regeneration Technology for S...

08.02.2017

Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

08.01.2017

Milestone Pharmaceuticals Closes $55 Million Series C Financing

07.25.2017

Kezar Life Sciences Announces Successful Completion of Phase 1a S...

05.25.2017

Liquidia Technologies Announces Positive Phase 1 Data for LIQ865,...

05.24.2017

New Pappas Capital Fund Makes First Investment

05.24.2017

OrphoMed Secures $39 Million Series A Financing Round

05.11.2017

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Pr...

03.27.2017

TESARO Announces U.S. FDA Approval of ZEJULA™ (niraparib) ...

03.07.2017

Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliv...

03.01.2017

Lilly Completes Acquisition of CoLucid Pharmaceuticals

02.03.2017

Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phas...

01.18.2017

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To...

10.17.2016

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data...

09.28.2016

Athersys Receives FDA Agreement Under Special Protocol Assessment...

09.06.2016

CoLucid Pharmaceuticals Announces Achievement of Both Primary and...

08.18.2016

Rotation Medical Secures $12 Million in Series B Extension Financing

07.18.2016

IlluminOss Medical Completes Enrollment for U.S. Clinical Trial U...

07.06.2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreemen...

06.10.2016

Merck to Acquire Afferent Pharmaceuticals

06.07.2016

CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMU...

05.19.2016

CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pi...

05.04.2016

Envisia Therapeutics Announces Positive Three-Month Interim Resul...

04.26.2016

Afferent Pharmaceuticals Announces Presentations of Chronic Cough...

03.23.2016

Envisia Therapeutics Secures $16.5 Million In Additional Series A...

03.02.2016

Syndax Announces Pricing of Initial Public Offering

03.01.2016

CoLucid Pharmaceuticals Announces Special Protocol Agreement for ...

02.29.2016

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Rang...

02.23.2016

CoLucid Pharmaceuticals Announces Confirmatory Support for Non-va...

02.17.2016

One-Year Results From Phase 2 Stroke Study of MultiStem® Cell The...

01.13.2016

Envisia Therapeutics Announces First Patient Dosed in Second Coho...

01.08.2016

Healios and Athersys Enter Into Regenerative Medicine Partnership...

01.05.2016

Afferent Pharmaceuticals named one of “The Hottest Startups...

01.04.2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collab...

12.08.2015

Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phas...

12.01.2015

Syndax Announces Initiation Of Entinostat Clinical Program In Jap...

11.30.2015

CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update

11.19.2015

Afferent Pharmaceuticals Expands Executive Leadership Team With A...

11.11.2015

Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF...

11.10.2015

Thrasos Strengthens Composition of Matter Coverage on THR-184 wit...

10.27.2015

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D....

10.09.2015

ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost ...

10.09.2015

Chimerix Presents Preliminary Data on Brincidofovir in Liver Tran...

10.09.2015

CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term...

10.09.2015

Medtronic TYRX(TM) Neuro Absorbable Antibacterial Envelope now Av...

10.08.2015

Wake Forest Baptist Medical Center Creates $15 Million Program to...

10.02.2015

Anthera Announces Initiation of the SOLUTION Clinical Study of Or...

09.30.2015

Liquidia Technologies and GlaxoSmithKline Advance Existing Collab...

09.28.2015

Afferent Pharmaceuticals Announces Positive Results in Phase 2b C...

09.17.2015

CardioDx Expands Patient Access to the Corus(R) CAD Test Through ...

09.02.2015

TESARO Announces U.S. FDA Approval of VARUBI™ (rolapitant)...

09.02.2015

Chimerix and BARDA Announce Continued Partnership in the Developm...

08.26.2015

SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAP...

08.24.2015

SYNDAX RAISES $80 MILLION IN SERIES C FINANCING

08.18.2015

Rotation Medical Featured in Local News Story

07.21.2015

IlluminOss Medical Appoints Clive Ridgwell as Vice President of S...

07.14.2015

Liquidia Technologies Names Robert A. Lippe Chief Operations Officer

07.08.2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study fo...

07.08.2015

Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Cro...

06.15.2015

Milestone Pharmaceuticals Closes US$17 Million Series B Financing...

05.06.2015

CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering

05.04.2015

Envisia Therapeutics to Present at ARVO 2015 Annual Meeting

04.29.2015

IlluminOss Medical Appoints Amy Orlick Berman as Vice President o...

04.28.2015

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Piv...

04.14.2015

Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer

03.31.2015

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 ...

03.31.2015

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluati...

03.24.2015

IlluminOss Medical Announces the Enrollment of First Patient in P...

03.19.2015

A drug that could raise IQ – Balance Therapeutics raises $1...

03.19.2015

Anthera Announces $3 Million Research Award from Cystic Fibrosis ...

03.16.2015

Anthera Pharmaceuticals Announces Completion of Interim Analysis ...

03.03.2015

IlluminOss Medical Announces the Enrollment of First Patient in E...

03.02.2015

Athersys and Chugai Enter License Agreement and Collaboration to ...

02.08.2015

Triangle Global Health Consortium Recognizes Chimerix with 2015 C...

01.27.2015

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515...

01.22.2015

Athersys and Cell Therapy Catapult Announce Grant to Support Clin...

01.13.2015

CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C P...

01.12.2015

Chimerix Receives Notice of Allowance for Brincidofovir Compositi...

01.12.2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phas...

01.07.2015

Ultragenyx Announces License of Intellectual Property Related to ...

01.07.2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocet...

01.07.2015

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreem...

01.06.2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored...

01.06.2015

Ultragenyx Initiates New Development Program Studying KRN23 for t...

01.05.2015

New Clinical Trial Will Evaluate Antibacterial Envelope in Cardia...

12.29.2014

Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cel...

12.23.2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of P...

12.18.2014

CardioDx Raises $35 Million in Equity Financing

12.18.2014

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collab...

12.15.2014

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Z...

12.15.2014

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant H...

12.10.2014

IlluminOss Medical Caps off Flagship Year with Addition of New Pa...

11.25.2014

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cou...

11.24.2014

Milestone Announces Positive Phase 1 Data for MSP-2017; Supports ...

11.18.2014

IlluminOss Medical Announces Conditional FDA Approval for Clinica...

11.13.2014

Chimerix’s Brincidofovir Selected for Use in Ebola Clinical...

11.08.2014

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ...

11.06.2014

Michael Grey Joins Mirati Therapeutics Board of Directors

10.30.2014

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the T...

10.28.2014

Chimerix hammers out an emergency PhII Ebola study for antiviral

10.27.2014

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for t...

10.20.2014

CardioDx Announces Results of Study Demonstrating the Benefits of...

09.25.2014

LabCorp Announces Agreement to Acquire LipoScience

09.22.2014

Medtronic Announces CE Mark and European Launch of TYRX(TM) Absor...

09.16.2014

Thrasos Announces Successful Formal Interim Analysis and Clinical...

09.15.2014

Rotation Medical Initiates Post-Market Clinical Study Of Rotator ...

09.15.2014

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 ...

09.08.2014

TESARO Announces Submission of Rolapitant New Drug Application (N...

08.11.2014

Mirati Therapeutics Receives Orphan Designation from U.S. Food &#...

08.05.2014

Ultragenyx Announces License of Intellectual Property for the Tre...

07.31.2014

New Data on Chimerix’s Brincidofovir Supports Safety and An...

07.30.2014

MedStar Union Memorial Hospital is First Hospital in Country to O...

07.14.2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (lipro...

07.07.2014

CardioDx Announces Aetna and Coventry Health Coverage for Corus® ...

07.01.2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for P...

07.01.2014

Rotation Medical Completes $27.2 Million Series B Financing

06.24.2014

Venture Partner Mike Grey named EY Entrepreneur Of The Year San D...

06.24.2014

Ultragenyx Announces Results from Phase 1/2 Study of KRN23 in X-l...

06.17.2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Fo...

06.03.2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents ...

05.14.2014

Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extensi...

05.12.2014

Shire adds to rare disease portfolio with acquisition of Lumena P...

05.12.2014

TESARO Announces Successful Achievement of Primary and All Second...

05.09.2014

Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 ...

05.06.2014

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA o...

05.05.2014

New Study Results Further Reinforce that the Corus® CAD Test Help...

04.30.2014

Ultragenyx Announces Positive Data From Phase 2 Study of Sialic A...

04.23.2014

MUSC Foundation for Research Development welcomes Art Pappas to b...

04.17.2014

IlluminOss receives new patents for bone stabilization system

03.27.2014

Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Rec...

03.11.2014

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

03.11.2014

Ultragenyx Announces First Patient Enrolled in Phase 2 Study of T...

03.10.2014

Study Finds the Corus® CAD Gene Expression Blood Test Influenced ...

02.24.2014

Marina Biotech Announces $6 MM Convertible Preferred Stock Financ...

02.12.2014

Ultragenyx Announces Presentation of Data From a Single Patient T...

02.11.2014

Ultragenyx Announces Initiation of Phase 2 Study for Patients wi...

02.06.2014

Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board...

02.06.2014

IlluminOss Medical introduces bone stabilization system in Spain,...

02.05.2014

Ultragenyx Announces Closing of Initial Public Offering and Exerc...

01.30.2014

Ultragenyx Announces Pricing of Initial Public Offering

01.22.2014

LipoScience Announces Appointment of Howard Doran as President an...

01.08.2014

Pappas Ventures Promotes Scott Weiner to Partner

01.06.2014

Medtronic Announces Acquisition of TYRX, INC., Developer of Solut...

12.20.2013

Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Ex...

12.17.2013

Ultragenyx Investigational New Drug Application for Triheptanoin ...

12.10.2013

Pappas Ventures Names Franz B. Humer as Venture Partner and Senio...

12.04.2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord N...

11.18.2013

Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug ...

11.12.2013

Envisia Therapeutics Debuts with $25 Million Series A Financing

11.05.2013

Inhibition of ASBT Improves Liver Function in an Animal Model of ...

10.29.2013

Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LU...

10.22.2013

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Di...

10.10.2013

New Data Highlight Value of Corus® CAD in Reducing Unnecessary Ca...

10.06.2013

Ultragenyx Announces the Presentation of Data from a Single Dose ...

10.02.2013

Chimerix Announces Publication of Positive Phase 2 Results of Bri...

09.26.2013

Ultragenyx Announces Three Abstracts Accepted for Poster Presenta...

09.26.2013

Lumena Pharmaceuticals Receives Orphan Drug Designation from US F...

09.26.2013

Lumena Pharmaceuticals Launches Global Clinical Program to Evalua...

09.24.2013

Ultragenyx selected as 2013 Fierce 15 Company

09.16.2013

Ultragenyx Announces Positive Data from Retrospective Study of UX...

09.11.2013

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results

09.09.2013

Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX00...

09.04.2013

LipoScience Announces New Data Supporting High-Density Lipoprotei...

09.03.2013

Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Deve...

08.27.2013

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing f...

08.14.2013

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus S...

08.14.2013

Ultragenyx Receives Approval of Clinical Trial Application (CTA) ...

08.12.2013

TYRX Announces First U.S. Implantation of AIGISRx® R Fully Biores...

08.05.2013

Ultragenyx Initiates New Development Program Studying Triheptanoi...

07.31.2013

LipoScience Research Sheds Light On Novel Markers Via Nuclear Mag...

07.23.2013

TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Pati...

07.23.2013

TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Enve...

07.23.2013

Stem cell therapy for transplants developed by Athersys Inc. may ...

07.15.2013

Chimerix CEO: Public market is critical to financing biotech R�...

07.11.2013

Ultragenyx Gains Worldwide Rights for Triheptanoin (UX007)

07.09.2013

TYRX Receives FDA Clearance for Fully Resorbable AIGISRx® R Antib...

07.03.2013

Ultragenyx Announces a Positive Signal in Interim Data from Phase...

06.28.2013

Mirati Therapeutics and MethylGene Announce Completion of Plan of...

06.28.2013

TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) ...

06.26.2013

Zero Infections in High-Risk Cardiac Device Replacements Reported...

06.24.2013

Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study ...

06.19.2013

Repurposing a cholesterol drug candidate for cholestatic liver di...

05.21.2013

Liquidia Technologies Announces Extension of Collaboration with P...

05.21.2013

Scott will provide his perspective on the investment outlook for ...

05.15.2013

Art Pappas Elected to NVCA Board of Directors

05.15.2013

Ultragenyx Advances Clinical Development of UX003 for the Treatme...

05.10.2013

Independent Study Shows Significant Decline in Cardiac Device Inf...

05.02.2013

Nanotechnology firm Liquidia plans new ophthalmology company

05.01.2013

Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Se...

05.01.2013

Ultragenyx Press Release: Ultragenyx Appoints Eric Yuen, MD as Ch...

04.22.2013

Jayson Punwani will moderate a discussion on Impact Investing at ...

04.22.2013

Scott Weiner will moderate a discussion on the current IPO market...

04.15.2013

TyRx Press Release – TYRX® Announces First EverImplantation...

04.15.2013

TYRX® Announces First EverImplantation of AIGISRx® R Fully Resorb...

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

UltraGenyx Press Release – Ultragenyx Initiates Novel Disea...

03.21.2013

Art Pappas will moderate the panel “Driving Innovation from...

03.20.2013

Art Pappas will join the panel, “The Research, Funding and ...

03.19.2013

Art Pappas joins a panel at the 2013 BIO International Convention...

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.20.2013

Ernest Mario named Chairman of Chimerix

02.20.2013

Ernest Mario named Chairman of Chimerix

02.11.2013

Art Pappas will join the panel, “How the Other Half Lives: ...

01.30.2013

LipoScience Press Release – LipoScience Announces Closing o...

01.30.2013

LipoScience Announces Closing of Initial Public Offering

01.25.2013

LipoScience Press Release – LipoScience Prices Initial Publ...

01.10.2013

Ultragenyx Press Release – Ultragenyx Announces In-Licensin...

01.10.2013

Ultragenyx Announces In-Licensing of Clinical-Stage Product Trihe...

01.10.2013

LipoScience Sets IPO Term

01.09.2013

LIPOSCIENCE COLLABORATES WITH A LEADING ACADEMIC MEDICAL CENTER T...

12.20.2012

Ultragenyx Press Release – Raises $75 Million in Oversubscr...

12.20.2012

Ultragenyx Press Release – Ultragenyx Raises $75 Million in...

12.20.2012

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.12.2012

Chimerix Press Release – Chimerix Appoints Michelle Berrey ...

11.12.2012

Chimerix Appoints Michelle Berrey Chief Medical Officer

10.29.2012

Jayson Punwani will moderate a panel at the 2nd annual Kenan-Flag...

10.25.2012

Thrasos Press Release – Thrasos Secures $35 Million to Fund...

10.25.2012

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Prog...

10.04.2012

TyRx Press Release – TYRX(R) Receives Health Canada Approval

10.04.2012

TYRX(R) Receives Health Canada Approval

10.02.2012

TyRx Press Release – FierceMedicalDevices Names TYRX® as on...

10.02.2012

FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medica...

10.02.2012

CardioDx Press Release – CardioDx Honored as One of FierceM...

10.02.2012

CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most P...

10.02.2012

Two Pappas Ventures’ Portfolio companies make FierceMedical...

09.27.2012

IlluminOss Press Release – IlluminOss Medical Secures $28 M...

09.27.2012

IlluminOss Medical Secures $28 Million Series C Financing for Min...

09.20.2012

Mike Grey will join a panel to discuss the future of venture capi...

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.14.2012

TyRx Press Release – TYRX(R) Receives New Product Innovatio...

09.14.2012

TYRX(R) Receives New Product Innovation Award

09.05.2012

LipoScience Press Release – LipoScience Receives FDA Cleara...

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

08.27.2012

CardioDx Press Release – CardioDx Completes $58 Million Equ...

08.27.2012

CardioDx Completes $58 Million Equity Financing

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.20.2012

TyRx Press Release – Over 50% of Hospital CFOs Plan to Adop...

08.20.2012

Art Pappas joins a Venture Capital Panel at Mid-Atlantic Bio on S...

08.14.2012

Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012...

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

07.31.2012

Scott Weiner will join a panel discussion around perspectives on ...

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Art Pappas makes TBJ “Triangle’s Most Influential Bus...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.25.2012

MethylGene announces encouraging data from Phase I tumor study

06.25.2012

MethylGene Announces Encouraging Data from Phase 1 Tumor Study

06.20.2012

Liquidia Announces Product Development Collaboration with GSK

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Technologies signs lucrative deal with GSK

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.05.2012

CED Selects Officers and Board of Directors Members

05.23.2012

Mike Grey will join a discussion panel entitled “Are we Hea...

05.16.2012

Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Dir...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Achillion gets FDA incentives for hepatitis C drug

05.15.2012

Achillion gets FDA Incentives for Hepatitis C Drug

05.14.2012

Scott will join a panel discussion focusing on raising US venture...

05.03.2012

Liquidia Founder Dr. Joseph DeSimone Elected into National Academ...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.23.2012

Ultragenyx Relocates Company Headquarters to Support Operational ...

04.19.2012

Syndax Pharmaceuticals Inc. Appoints Arlene Morris as CEO

04.06.2012

Liquidia figuring out how to ‘unleash’ technology

04.06.2012

Orphan Diseases and the Future of BioPharma, the Focus of the 201...

04.06.2012

Syndax Pharmaceuticals Inc. Appoints Arthur M. Pappas to Board of...

04.03.2012

Liquidia CEO to Participate in Biotech Panel to Explore “How to C...

04.02.2012

Big business appeal of nanotechnology on display in Durham

04.02.2012

Big Business Appeal of Nanotechnology on Display in Durham

04.02.2012

What venture capitalists look for in personalized medicine invest...

03.28.2012

Turner will provide his perspective on adopting personalized medi...

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.26.2012

Tesaro promises rapid progress with cancer drugs in $86M IPO

03.26.2012

TESARO promises rapid progress with cancer drugs in $86M IPO

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.19.2012

Art will provide featured remarks to the Harvard Business School ...

03.19.2012

Art Pappas will participate on a panel to discuss exit strategies...

03.15.2012

Hagan Bill Could Speed Approval Process for Drugs

03.14.2012

Marina, ProNAi in cancer deal

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.06.2012

Eric Linsley offers perspective on personalized medicine’s develo...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

02.29.2012

Art Pappas will moderate and lead a discussion entitled “Ar...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.21.2012

Eric Linsley will lead a discussion on “Partnering and Lice...

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.08.2012

Scott Weiner will present and sit on a panel at the IN3 Medical D...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.02.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

02.01.2012

A Path Forward for the FDA

02.01.2012

A Path Forward for the FDA

02.01.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

01.31.2012

Eric Linsley speaks on CED Life Science

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.23.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

PRINTed Nanoparticles Delivery Multiple Punches to Treat Prostate...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Art Pappas speaks on life sciences innovation at Biotech Showcase...

01.09.2012

FDA New Drug Approvals in 2011 Outpace Recent Past

01.04.2012

Achillion hepatitis drug gets faster FDA review

01.04.2012

ACH-1625 Receives Fast Track Designation From the FDA for the Tre...

12.28.2011

Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and Mirna Th...

12.28.2011

Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and Mirna Th...

12.23.2011

A look back, and forward

12.19.2011

Roche’s Zelboraf Melanoma Drug Wins Backing of EU Regulator

12.19.2011

Emil Kakkis harvesting academic sources for Orphan drug newco Ult...

12.13.2011

Nanotechnology firm Liquidia partners with PATH on new pneumonia ...

12.13.2011

Nanotechnology firm Liquidia partners with PATH on new pneumonia ...

12.12.2011

Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood...

12.12.2011

Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood...

12.09.2011

CeNeRx, expecting trial results and drug partner in 2012, raises ...

12.09.2011

CeNeRx, expecting trial results and drug partner in 2012, raises ...

12.08.2011

Survival Benefit With Syndax Pharmaceuticals’ Entinostat Ma...

12.08.2011

Finding satisfaction in stratification

12.08.2011

Finding satisfaction in stratification

12.08.2011

Survival Benefit With Syndax Pharmaceuticals’ Entinostat Ma...

12.01.2011

Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEAR...

12.01.2011

Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEAR...

11.29.2011

More Big Foundations Are Investing in For-Profits

11.29.2011

More Big Foundations Are Investing in For-Profits

11.29.2011

FierceBiotech’s 2011 Women in Biotech – Plexxikon Pre...

11.29.2011

FierceBiotech’s 2011 Women in Biotech – Plexxikon Pre...

11.21.2011

Achillion to Present at the 23rd Annual Piper Jaffray Health Care...

11.18.2011

Personalized medicine’s opportunities and challenges for clinicia...

11.18.2011

Personalized medicine’s opportunities and challenges for clinicia...

11.15.2011

CardioDx Passes Trial, Determining When Chest Pain Is No Big Deal

11.15.2011

CardioDx Passes Trial, Determining When Chest Pain Is No Big Deal

11.13.2011

Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks

11.11.2011

Barry Myers will be speaking on a panel discussing financing mech...

11.09.2011

Syndax: Epigenetic Therapy Shows Promise in Hard-to-treat Lung Ca...

11.09.2011

Epigenetic Therapy Shows Promise in Hard-to-treat Lung Cancer

11.03.2011

Eric will join a panel discussion on the challenges facing person...

10.31.2011

Scott Weiner will participate on the panel “Can the Rest of the W...

10.31.2011

Barry Myers will be speaking on a panel discussing trends in Biom...

10.26.2011

Anthera Pharmaceuticals, Inc. (ANTH) Announces Last Patient Enrol...

10.26.2011

Anthera Pharmaceuticals, Inc. (ANTH) Announces Last Patient Enrol...

10.18.2011

FDA Approves Plexxikon Drug

10.18.2011

FDA Approves Plexxikon Drug

10.07.2011

Plexxikon’s Glaub: personalized medicine is ‘the wave of the future’

10.07.2011

Plexxikon’s Glaub: personalized medicine is ‘the wave of the future’

10.03.2011

M&A Still Bright Spot For VCs

10.03.2011

M&A Still Bright Spot For VCs

09.16.2011

Chimerix Announces Late-Breaker Presentation At 51st Interscience...

09.16.2011

Chimerix Announces Late-Breaker Presentation At 51st Interscience...

09.06.2011

Syndax Pharmaceutical’s Positive Phase 2 Data Supports Pote...

09.06.2011

Syndax Pharmaceutical’s Positive Phase 2 Data Supports Pote...

09.06.2011

Tesaro – 2011 Fierce 15

08.30.2011

CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million

08.30.2011

CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million

08.20.2011

CoLucid Pharmaceuticals Receives Clearance For Investigational Ne...

08.20.2011

CoLucid Pharmaceuticals Receives Clearance For Investigational Ne...

08.18.2011

CoLucid in talks with partners for novel migraine treatment

08.17.2011

Genentech, Plexxikon Cancer Drug Gets FDA OK

08.17.2011

Genentech, Plexxikon Cancer Drug Gets FDA OK

08.17.2011

Syndax Pharmaceuticals Inc. Announces Issuance of EU Patent for E...

08.17.2011

Syndax Pharmaceuticals Inc. Announces Issuance of EU Patent for E...

08.10.2011

Vemurafenib Will Open Floodgates for Melanoma Genotyping

08.10.2011

Vemurafenib Will Open Floodgates for Melanoma Genotyping

07.15.2011

CoLucid Appoints Thomas P. Mathers as Chief Executive Officer Re...

07.08.2011

Marina Biotech Reports Significant Developments in Its Ability to...

06.29.2011

Art Pappas will be speaking on two panels, Starting Up Biotechs i...

06.28.2011

Scott Weiner will be moderating a panel, The Partnering Conundrum...

06.27.2011

CED picks Pappas, Channel Advisor execs

06.26.2011

A Rare Disease Pioneer Scores $45 Million for New Company

06.24.2011

Diabetes drug company Lumena raising up to $2M to reach clinical ...

06.24.2011

Diabetes drug company Lumena raising up to $2M to reach clinical ...

06.24.2011

N.C. diagnostics firm LipoScience files for $86M IPO

06.24.2011

N.C. diagnostics firm LipoScience files for $86M IPO

06.22.2011

Achillion Initiates 12-Week Dosing in Phase 2 Trial of ACH-1625 f...

06.22.2011

Achillion Initiates 12-Week Dosing in Phase 2 Trial of ACH-1625 f...

06.21.2011

Tesaro Garners $101,000,000 Series B Financing Round

06.21.2011

Tesaro Garners $101,000,000 Series B Financing Round

06.20.2011

Canada-U.S. syndicate back Milestone Pharma’s oral drug for...

06.20.2011

Ultragenyx Announces Series A Financing

06.20.2011

Ultragenyx Announces Series A Financing

06.17.2011

Pappas Ventures-Backed Lumena Pharma Bumps up Debt Offering to $2...

06.16.2011

Anthera Pharmaceuticals Announces Proposed Public Offering of Com...

06.15.2011

Are Early Clinical Successes Enough to Bring RNAi Back from the B...

06.13.2011

One-Year Follow-Up Results From Athersys’ Phase I Study of ...

06.13.2011

Milestone completes $13 million round of equity financing

06.13.2011

Milestone completes $13 million round of equity financing

06.11.2011

Studies find new drugs boost skin-cancer survival

06.11.2011

Studies find new drugs boost skin-cancer survival

05.10.2011

Mike Grey will be moderating a panel discussion on strategies for...

05.04.2011

Mike Grey will be speaking on a panel, Driving Life Sciences Disc...

04.04.2011

Plexxikon, Daiichi Sankyo complete potential $935M deal

04.04.2011

Plexxikon, Daiichi Sankyo complete potential $935M deal

04.01.2011

Taking Aim at Melanoma – The Scientist – Magazine of ...

03.30.2011

Achillion Announces Positive RVR Results With ACH-1625 to Treat C...

03.30.2011

Achillion Announces Positive RVR Results With ACH-1625 to Treat C...

03.28.2011

Selventa Announces a Joint Technology Collaboration with Pfizer I...

03.28.2011

Selventa Announces a Joint Technology Collaboration with Pfizer I...

03.08.2011

Gates Foundation Makes First Equity Investment in a Biotech Start...

03.08.2011

Gates Foundation Makes First Equity Investment in a Biotech Start...

03.04.2011

Liquidia Technologies receives significant equity investment to b...

03.01.2011

Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinost...

03.01.2011

Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinost...

02.28.2011

Daiichi Sankyo to Acquire Plexxikon

02.28.2011

Daiichi Sankyo to Acquire Plexxikon

02.22.2011

Scott Weiner will speak about Pappas Ventures’ perspective ...

02.16.2011

Art Pappas will be on a panel at the UNC Alternative Investments ...

02.16.2011

Chimerix Awarded BARDA Contract for Advanced Development of CMX00...

02.14.2011

Chimerix Completes $45 Million Financing to Fund Further Developm...

02.14.2011

Chimerix Completes $45 Million Financing to Fund Further Developm...

02.03.2011

Marina Biotech and The Debiopharm Group Partner to Develop and Co...

02.03.2011

Marina Biotech and The Debiopharm Group Partner to Develop and Co...

01.19.2011

Researchers From Case Western Reserve and Athersys Publish Landma...

01.19.2011

Researchers from Case Western Reserve and Athersys Publish Landma...

01.18.2011

Plexxikon Reports Overall Survival Benefit for Melanoma Patients ...

01.18.2011

Plexxikon Reports Overall Survival Benefit for Melanoma Patients ...

12.08.2010

TYRX, Inc. raises $20 million in private financing

12.08.2010

TYRX, Inc. raises $20 million in private financing

11.30.2010

Genstruct, Inc. changes name to Selventa as company launches re-b...

11.30.2010

Genstruct, Inc. changes name to Selventa as company launches re-b...

11.09.2010

Scott Weiner is participating on a panel at the Greater Philadelp...

10.27.2010

Art Pappas will speak about future trends in biotechnology at the...

10.26.2010

Marina Biotech announces interim safety results of long-term toxi...

10.21.2010

Art Pappas will speak on “Later Stage Venture Funding”...

10.19.2010

TYRX AIGISRx® antibacterial envelope shows low infection rate and...

10.19.2010

TYRX AIGISRx® antibacterial envelope shows low infection rate and...

10.09.2010

Mike Grey will speak on “What Are the Funding Sources and H...

10.06.2010

Liquidia begins testing flu vaccine

10.04.2010

Gene test may improve heart disease detection

09.22.2010

Marina Biotech announces first human use of its proprietary deliv...

09.22.2010

Marina Biotech announces first human use of its proprietary deliv...

09.21.2010

Anthera Pharmaceuticals announces pricing of $31.5 million PIPE f...

09.21.2010

Anthera Pharmaceuticals announces pricing of $31.5 million PIPE f...

09.15.2010

“Plexxikon – 2010 Fierce 15” – FierceBiotech

09.13.2010

Marina Biotech, Inc. announces significant knockdown of gene targ...

08.25.2010

Plexxikon publishes PLX4032 Phase 1 data in the New England Journ...

08.25.2010

Plexxikon publishes PLX4032 Phase 1 data in the New England Journ...

08.18.2010

Achillion Announces Private Placement of $50 Million

08.18.2010

Achillion Announces Private Placement of $50 Million

06.09.2010

CoLucid Pharmaceuticals, Inc. announces study data documenting or...

06.09.2010

CoLucid Pharmaceuticals, Inc. announces study data documenting or...

05.19.2010

Art Pappas to participate on panel, “Investing in Neurotech...

05.13.2010

GE Healthcare forms strategic alliance with cardiovascular genomi...

05.13.2010

GE Healthcare forms strategic alliance with cardiovascular genomi...

05.05.2010

Sean McCarthy to moderate panel, “Bridges Over Troubled Wat...

05.05.2010

Art Pappas to moderate panel, “Accessing Capital through Ri...

04.27.2010

FDA provides clearance of TyRx antibacterial patch for soft tissu...

04.27.2010

FDA provides clearance of TyRx antibacterial patch for soft tissu...

04.20.2010

Liquidia Technologies has added an additional investor, PPD, Inc....

04.20.2010

Liquidia Technologies has added an additional investor, PPD, Inc....

04.15.2010

Cequent begins chronic toxicology study

04.15.2010

Cequent begins chronic toxicology study

04.13.2010

TyRx announces commercial release of the AIGISRx™ Flat

04.13.2010

New Anti-Bacterial Device Helps Reduce Infections Associated with...

04.01.2010

MDRNA, Inc. acquires Cequent Pharmaceuticals

04.01.2010

MDRNA, Inc. acquires Cequent Pharmaceuticals

03.24.2010

TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bac...

03.24.2010

TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bac...

03.04.2010

Anthera Pharmaceuticals completes initial public offering

03.04.2010

Anthera Pharmaceuticals completes initial public offering

03.01.2010

CardioDx – Bringing molecular diagnostics into the cardiova...

03.01.2010

“The Business of Biotechnology”

03.01.2010

CardioDx – Bringing molecular diagnostics into the cardiova...

02.24.2010

AutoGenomics announces the launch of a novel test for B-RAF mutat...

02.10.2010

Athersys receives U.S. Patent covering adult stem cell compositio...

02.10.2010

Athersys receives U.S. Patent covering adult stem cell compositio...

02.09.2010

Sequenom licenses worldwide rights to develop age-related macular...

02.09.2010

Sequenom licenses worldwide rights to develop age-related macular...

02.04.2010

BioMarin to acquire LEAD Therapeutics

02.04.2010

BioMarin to acquire LEAD Therapeutics

01.19.2010

Liquidia Technologies Raises $20 Million Financing

01.19.2010

Liquidia Technologies Raises $20 Million Financing

01.11.2010

Pappas Ventures names Michael Grey Venture Partner

12.21.2009

Athersys Strikes Deal With Pfizer to Develop Stem Cell Technology...

12.21.2009

Athersys Strikes Deal With Pfizer to Develop Stem Cell Technology...

12.16.2009

VCs Invest $23M In Roche Holding Spinout Afferent Pharmaceuticals

12.16.2009

Roche Licenses First-in-Class Treatments for Chronic Pain to Affe...

12.16.2009

Roche Licenses First-in-Class Treatments for Chronic Pain to Affe...

12.04.2009

This New Technology Simply Saved My Legs

11.01.2009

Death of the 20-minute Rule

10.28.2009

Arthur M. Pappas Elected as Biotechnology Center Board Chairman

10.19.2009

Sean McCarthy is participating in a panel at the Financing Soluti...

09.29.2009

Pappas Picks Likely Heir, Prepares for More IPOs

09.29.2009

Plexxikon announces first patient dosed in first of two pivotal t...

09.29.2009

Plexxikon announces first patient dosed in first of two pivotal t...

09.28.2009

Pappas Ventures Names Eric Linsley Managing Partner

09.15.2009

LEAD Therapeutics presents new antibiotic with potent activity ag...

09.15.2009

LEAD Therapeutics presents new antibiotic with potent activity ag...

09.09.2009

NC Biotech Center building $10M HQ addition

09.09.2009

NC Biotech Center building $10M HQ addition

08.25.2009

CardioDx completes validation study of first-of-its-kind genomic ...

08.25.2009

CardioDx completes validation study of first-of-its-kind genomic ...

08.21.2009

Art Pappas is participating in a health reform panel discussion f...

07.27.2009

Unlikely treatment identified by Braincells neurogenesis platform...

07.27.2009

Unlikely treatment identified by Braincells neurogenesis platform...

07.02.2009

Plaque Piercing Device Relieves Patients’ Clogged Arteries

06.15.2009

BioWorld interview with Sean McCarthy

06.15.2009

CeNeRx Biopharma completes $9 million financing

06.15.2009

CeNeRx Biopharma completes $9 million financing

06.10.2009

Bayhill Therapeutics enters exclusive, worldwide collaboration wi...

06.10.2009

Bayhill Therapeutics enters exclusive, worldwide collaboration wi...

06.04.2009

Art Pappas will participate on a panel titled “Life Science...

05.21.2009

Sean McCarthy will participate on a panel titled “Specialty...

05.14.2009

Jeff Collins will participate on a panel titled “Funding In...

05.14.2009

Scott Weiner appointed to Strategic Advisory Board of Florida Ins...

05.14.2009

TargeGen successfully completed enrollment of a multi-center clin...

05.14.2009

Tyrx presents early clinical results from AIGISRXTM antibacterial...

05.14.2009

TargeGen successfully completed enrollment of a multi-center clin...

05.14.2009

Tyrx presents early clinical results from AIGISRXTM antibacterial...

05.11.2009

Art Pappas will speak at the Personalized Medicine in North Carol...

05.06.2009

Anthera’s varespladib meets primary endpoint in phase 2 FRA...

04.28.2009

Art Pappas will participate on a panel titled “Beyond Emerg...

04.22.2009

Eric Linsley will participate on a panel titled “Leadership...

04.08.2009

Art Pappas will participate on a panel at the C21 BioVentures Con...

03.30.2009

Cardiac “Jackhammer” Destroys Arterial Plaque

03.30.2009

Cardiac “Jackhammer” Destroys Arterial Plaque

03.26.2009

Ranch Cardiologist Performs New Surgery

03.24.2009

Anthera to continue impacts trial for the prevention of acute che...

03.24.2009

Anthera to continue impacts trial for the prevention of acute che...

03.10.2009

Pappas Ventures closes on fourth fund

03.10.2009

Pappas Ventures closes on fourth fund

02.25.2009

Genstruct and Gene Logic collaborate on systems toxicology

02.25.2009

Genstruct and Gene Logic collaborate on systems toxicology

02.12.2009

Cequent releases primate safety, efficacy data for oral FAP therapy

02.12.2009

Cequent releases primate safety, efficacy data for oral FAP therapy

01.22.2009

Art Pappas will participate on a panel called “Venture Capi...

01.08.2009

Plexxikon and Roche enter second partnership

01.08.2009

Plexxikon and Roche enter second partnership

12.08.2008

Arthur Klausner to participate in the panel “Alternatives f...

10.30.2008

Arthur Klausner to sit on the “VC Check-Up” panel at ...

10.28.2008

Arthur M. Pappas elected Board Chairman of North Carolina Biotech...

10.21.2008

Art Pappas will be on a panel titled “Update on Capital Ava...

10.17.2008

CeNeRx BioPharma completes $15 Million Series B financing

10.17.2008

CeNeRx BioPharma initiates Phase 2 clinical trial of its novel an...

10.15.2008

Jeff Collins to sit on the review panel for the Life Science Comp...

10.06.2008

Art Pappas will speak at the Drug Repositioning Summit on October...

09.23.2008

Anthera completes special protocol assessment with FDA and receiv...

09.06.2008

Phase 2 Results of COL-144 Presented at European Headache and Mig...

09.05.2008

CoLucid presents Phase 2 results of COL-144 at European Headache ...

09.03.2008

Plexxikon initiates Phase 1 Trial for PLX5568

09.03.2008

Plexxikon initiates Phase 1 Trial for PLX5568

08.25.2008

Anthera advances global development strategy for varespladib with...

08.25.2008

Anthera advances global development strategy for varespladib with...

08.04.2008

Arthur Klausner to speak at the 13th Annual Drug Discovery &...

07.22.2008

CeNeRx BioPharma to initiate Phase 2 trials for its novel antidep...

07.22.2008

CeNeRx BioPharma to initiate Phase 2 trials for its novel antidep...

07.11.2008

Art Pappas will sit on a panel at the Biotechnologia 2007 Confere...

07.11.2008

Art Pappas to participate at Foundation Sante Biotechnology Confe...

07.01.2008

CoLucid announces $25 million Series B financing for advancement ...

07.01.2008

CoLucid announces $25 million Series B financing for advancement ...

06.25.2008

Methylgene announces the initiation of a Phase 2 trial of MGCD0103

06.25.2008

Methylgene announces the initiation of a Phase 2 trial of MGCD0103

06.17.2008

Sean McCarthy will participate on a panel at the BIO Internationa...

06.17.2008

Arthur Klausner will participate on a panel at the Biotechnology ...

06.13.2008

Jeff Collins will participate in the US-India BioPharma Summit (t...

05.21.2008

Plexxikon announces preclinical data demonstrating dramatic impro...

05.21.2008

Plexxikon announces preclinical data demonstrating dramatic impro...

05.20.2008

Dynogen presents results of its positive Phase 2 IBS-d study with...

05.20.2008

Dynogen presents results of its positive Phase 2 IBS-d study with...

05.19.2008

Jeff Collins was elected to a 3-year term on the Board of Directo...

05.08.2008

Jeff Collins to sit on a panel titled “Investing in Neurote...

04.30.2008

Scott Weiner to join panel at 2nd Annual Global Healthcare Invest...

04.30.2008

Genstruct and Sirtris Pharmaceuticals win Bio-IT World’s Be...

04.30.2008

Genstruct and Sirtris Pharmaceuticals win Bio-IT World’s Be...

04.28.2008

Eric Linsley to speak at CED’s Biotech Forum: “How Ea...

04.24.2008

Jeff Collins will serve as a judge in the Commercializing Innovat...

04.24.2008

Art Pappas to sit on a panel titled “Venture Funding”...

04.17.2008

BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for...

04.17.2008

BrainCells expands Series B financing to $50 million

04.17.2008

BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for...

04.17.2008

BrainCells expands Series B financing to $50 million

04.16.2008

Eric Linsley will co-chair the CED’s 25th Annual Venture Co...

04.16.2008

Panacos Attracts $18.3M Round To Fund HIV Drug Development (BioWo...

04.16.2008

DSMB supports continuation of Anthera Phase 2 impacts trial for t...

04.16.2008

Bayhill Therapeutics presents data from a Phase 2 trial of BHT-30...

04.16.2008

MethylGene initiates Phase 1 clinical trial for its multi-targete...

04.16.2008

DSMB supports continuation of Anthera Phase 2 impacts trial for t...

04.16.2008

Bayhill Therapeutics presents data from a Phase 2 trial of BHT-30...

04.16.2008

MethylGene initiates Phase 1 clinical trial for its multi-targete...

04.07.2008

UCSD, TargeGen team-up on blood disease treatment

03.27.2008

LipoScience: LDL particle measurement by NMR recognized in consen...

03.27.2008

LipoScience: LDL particle measurement by NMR recognized in consen...

03.19.2008

Genstruct: Patience, Persistence, and Payoff

03.19.2008

Genstruct: Patience, Persistence, and Payoff

03.17.2008

BioSyntech announces positive preliminary interim data for BST-Ca...

03.17.2008

BioSyntech announces positive preliminary interim data for BST-Ca...

03.10.2008

Art Pappas is on the steering committeee of the “Partnering...

03.08.2008

Barry Myers is a featured speaker at CED’s MedTech 2008 Con...

03.04.2008

Biovitrum and Syntonix set to begin Phase 1/2a clinical trial for...

02.28.2008

TyRx Pharma raises $25 million

02.28.2008

TyRx Pharma raises $25 million

02.27.2008

Athersys announces summary results for Phase 1 safety study of it...

02.27.2008

Athersys announces summary results for Phase 1 safety study of it...

02.20.2008

Genstruct announces new collaboration with Pfizer in drug safety

02.20.2008

Genstruct announces new collaboration with Pfizer in drug safety

02.14.2008

Art Pappas will participate on a panel entitled “Invest Glo...

02.14.2008

MethylGene and Pharmion announce orphan drug designation for trea...

02.14.2008

MethylGene and Pharmion announce orphan drug designation for trea...

02.06.2008

Apex Bioventures and Dynogen Pharmaceuticals announce definitive ...

02.06.2008

Apex Bioventures and Dynogen Pharmaceuticals announce definitive ...

01.31.2008

Anthera enters into manufacturing agreements for Varespladib in p...

01.31.2008

TargeGen announces initiation of clinical trial of JAK2 inhibitor...

01.31.2008

Anthera enters into manufacturing agreements for Varespladib in p...

01.21.2008

Arthur Klausner to be a panelist at the 12th Annual Drug Delivery...

01.16.2008

Dynogen expands DDP225 patent estate

01.16.2008

Dynogen expands DDP225 patent estate

01.15.2008

Anthera announces preliminary positive results from once-daily A-...

01.15.2008

Anthera announces preliminary positive results from once-daily A-...

01.09.2008

Bayhill Therapeutics files registration statement for proposed in...

01.09.2008

Bayhill Therapeutics files registration statement for proposed in...

12.18.2007

Anthera receives orphan drug status for the prevention of acute c...

12.17.2007

Dynogen announces positive results in Phase 2 IBS-d study

12.11.2007

FlowCardia launches peripheral CROSSER catheters in the US

12.10.2007

Sean McCarthy to be a panelist at CED’s Business Developmen...

12.10.2007

MethylGene and Pharmion present favorable clinical data from comb...

12.09.2007

MethylGene and Pharmion report favorable results for Phase 2 sing...

11.15.2007

Scott Weiner to be panelist at PricewaterhouseCooper’s R...

11.15.2007

Athersys authorized for Phase 1 clinical trial in bone marrow tra...

11.14.2007

Arthur Klausner to speak at “NC Early-Stage Breakfast”...

11.14.2007

LEAD Therapeutics announces strategic research collaboration with...

11.08.2007

Dynogen begins Phase 2b trial for IBS with constipation drug

11.05.2007

LEAD Therapeutics raises $17 million in Series A financing

10.25.2007

Panacos announces greater than 1 Log10 mean reduction in 300 mg b...

10.24.2007

MethylGene and Pharmion report preliminary clinical data at the 2...

10.24.2007

Anthera announces positive Phase II clinical results from A-002 c...

10.23.2007

Arthur Klausner will be a panelist at “The Venture Prognosi...

10.17.2007

Art Pappas will participate on a panel at BioFlorida’s 10th...

10.15.2007

Dynogen announces the presentation of its positive Phase 1b trial...

10.12.2007

Sean McCarthy will participate on a panel at the Charlotte Biotec...

10.09.2007

Optherion completes $37 million start up financing

10.03.2007

Art Pappas will serve on the International Finance Panel at BioCo...

09.27.2007

BrainCells, Taisho Pharmaceutical, sign licensing agreement for n...

08.30.2007

FlowCardia today announced it has raised $30 million in Series C ...

08.20.2007

Methylgene and Pharmion announce collaboration to develop sirtuin...

07.30.2007

TargeGen initiates Phase II clinical trial of topically-applied d...

07.25.2007

Athersys begins Phase I trial for ATHX-105 for treatment of obesity

07.12.2007

TargeGen closes on $40 million venture round

06.18.2007

Arthur Klausner to be a featured speaker at CED Biotech Forum: Tr...

05.26.2007

Dr. Sean McCarthy, PhD, will speak at the Duke Beijing Healthcare...

05.06.2007

Art Pappas will sit on a panel at the 2007 BIO International Conv...

04.19.2007

Art Pappas will be a panelist at the Small and Emerging Private E...

04.13.2007

Syndax Pharmaceuticals licenses selective histone deacetylase inh...

04.11.2007

Art Pappas will sit on a panel titled “Getting the Funds Yo...

04.03.2007

Syndax Pharmaceuticals closes $40 Million Series A Financing

03.22.2007

Sean McCarthy will join a roundtable discussion of “How to ...

02.26.2007

Getting Closer to Nature: The BrainCells Way

02.13.2007

Dynogen reports positive results in Phase 2 IBS-c study

01.31.2007

CeNeRx BioPharma initiates human trials of RIMA antidepressant

01.23.2007

FlowCardia, Inc. announces 510(k) clearance for its chronic total...

01.04.2007

Biogen Idec to acquire Syntonix Pharmaceuticals

12.14.2006

Cerexa to be acquired by Forest Laboratories for $480 million plu...

11.01.2006

Cerexa expands portfolio of novel anti-infective therapies throug...

11.01.2006

TargeGen initiates Phase I clinical trial of topical AMD drug TG1...

10.23.2006

BrainCells and Organon to collaborate in discovery and developmen...

09.26.2006

Arthur Klausner will sit on a panel at the 11th Annual Drug Deliv...

09.14.2006

Arthur Klausner to speak at Biotech & Life Science Global Ve...

09.13.2006

Dynogen initiates phase 1b trial of DDP733 in gastroesophageal re...

09.13.2006

Anthera Pharmaceuticals secures $36m venture financing to initiat...

09.06.2006

Anthera licenses anti-inflammatory products from Eli Lilly and Sh...

08.15.2006

Art Pappas to participate in panel discussion on “The Impac...

05.31.2006

Panacos Announces Study Elucidating PA-457’s Mechanism of A...

05.18.2006

Arthur Klausner to speak at FundingPost’s early-stage VC br...

05.10.2006

Eric Linsley to join panel at the MedTech Investing Conference in...

05.04.2006

Methylgene Completes Private Placement of $19.9 Million

04.22.2006

Jeff Collins to serve as a judge for the 2nd Carolina Entrepreneu...

04.17.2006

Arthur Klausner will be a panelist at the New York Biotechnology ...

04.15.2006

Charles Hsu will be a keynote speaker at the annual meeting of th...

04.10.2006

Bayhill Therapeutics Raises an Additional $15.8 Million

03.14.2006

FDA Grants Cerexa Fast Track Designation for PPI-0903

01.17.2006

CoLucid Pharmaceuticals Announces $16.5 Million Series A Financing

12.02.2005

Significant Decision Gives Patients Better Access to LipoScience&...

11.29.2005

CeNeRx BioPharma Announces $18.5 Million Series A Financing

10.24.2005

After Change Up Top, Syntonix Inks Boehringer Ingelheim Deal Wort...

10.21.2005

Syntonix and Boehringer Ingelheim Enter Collaboration for Up to $...

10.18.2005

BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer

10.17.2005

Dynogen Initiates Phase II Trial of Ddp225 for Treatment of Patie...

09.12.2005

A Better Way to Ambush Aids? Panacos Pharmaceutical’s exper...

07.28.2005

TargeGen, Inc. Selects Lead Drug for Clinical Development As A To...

07.15.2005

BrainCells Gets $8M In First Part Of Committed $17.7M Series A

05.12.2005

Spherics Secures $26.4M Financing to Advance Clinical Programs Ba...

05.04.2005

Bayhill Therapeutics raises $35.4 million in Series B financing

03.31.2005

Serono and Syntonix Sign Worldwide Agreement to Develop and Comme...

03.11.2005

Vitex Closes Merger with Panacos Pharmaceuticals $20 Million Fina...

01.10.2005

A. M. Pappas & Associates Names Charles Hsu as Venture Partn...

12.20.2004

Bioinformatics on the Brink (The Scientist)

11.01.2004

Plexxikon, Wyeth PPAR Deal: Up to $372M In Diabetes Bid (BioWorld...

06.04.2004

Panacos, Vitex Merging In $27M Stock Exchange, Plus Milestones (B...

05.27.2004

Plexxikon Gets $15M Investment For Diabetes Drug Development (Bio...

04.20.2004

Dynogen’s GI, GU Products To Benefit From $50M Round (BioWo...

04.19.2004

Dynogen Pharma gets $50M round (TheDeal.com)

01.20.2004

Genstruct Applying Epistemics Approach To ‘Molecular World&...

12.15.2020

BioAtla Announces Pricing of Initial Public Offering

12.10.2020

4D Molecular Therapeutics Announces Upsized Pricing of Initial Pu...

12.09.2020

Reneo Pharmaceuticals Raises $95 Million in Series B Financing, C...

11.30.2020

Mirum Pharmaceuticals Announces European Medicines Agency Validat...

11.05.2020

VelosBio to be Acquired by Merck for $2.75 billion

10.22.2020

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-10...

09.10.2020

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug ...

08.19.2020

4D Molecular Therapeutics Announces First Patient Dosed in Phase ...

08.17.2020

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV ...

07.30.2020

Cyclerion Therapeutics Completes $24 Million Private Placement

07.15.2020

BioAtla Raises $72.5 Million In Series D Financing

07.08.2020

VelosBio Raises $137 Million in Series B Financing

06.16.2020

4D Molecular Therapeutics Raises $75 Million in Series C Financing

05.19.2020

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financin...

05.19.2020

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, ...

05.01.2020

HealthpointCapital Acquires Majority Stake in IlluminOss Medical,...

04.02.2020

Curzion Pharmaceuticals Acquired by Horizon Therapeutics

01.27.2020

Liquidia Submits New Drug Application for LIQ861 (treprostinil) i...

12.16.2019

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with F...

10.23.2019

Allievex Completes Series A Financing Led by Pappas Capital and N...

10.11.2019

Former CoLucid Drug, Lasmiditan, Receives FDA Approval

09.30.2019

Vertex and Ribometrix Establish Strategic Collaboration to Discov...

09.27.2019

Ribometrix Announces $7.8 Million in New Funding to Advance RNA-T...

09.16.2019

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Vir...

09.16.2019

Amplyx Pharmaceuticals Announces Positive Preliminary Data from O...

09.11.2019

Alex Arfaei Joins Pappas Capital As Partner

09.09.2019

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for Fosman...

07.17.2019

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

07.16.2019

Pappas Capital Expands Leadership Team With Appointments Of Kyle ...

05.20.2019

Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics ...

05.09.2019

Milestone Pharmaceuticals Announces Pricing of Upsized Initial Pu...

02.28.2019

IlluminOss Medical Launches the IlluminOss® Bone Stabilization Sy...

01.07.2019

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data...

11.13.2018

Ribometrix Announces $30 Million Series A Funding to Advance Pipe...

11.07.2018

Mirum Pharmaceuticals Secures $120 Million in Series A Financing

10.25.2018

Milestone Pharmaceuticals Announces $80 Million Private Financing

10.17.2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing

10.01.2018

VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Cl...

09.05.2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

08.08.2018

Milestone Pharmaceuticals Announces First Patient Randomized in t...

07.25.2018

Liquidia Technologies Announces Pricing of Initial Public Offering

06.20.2018

Kezar Life Sciences Announces Pricing of Initial Public Offering

04.25.2018

FDA Grants Fast Track Designation for OrphoMed’s ORP-101 fo...

04.10.2018

Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner

03.19.2018

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectiou...

01.10.2018

IlluminOss Medical Granted FDA Marketing Clearance for the Illumi...

01.03.2018

Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients w...

12.06.2017

Pappas Capital Portfolio Company Rotation Medical Acquired by Smi...

12.06.2017

Smith & Nephew Completes Acquisition of Rotation Medical Inc.

10.23.2017

Smith & Nephew Acquires Tissue Regeneration Technology for S...

08.02.2017

Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

08.01.2017

Milestone Pharmaceuticals Closes $55 Million Series C Financing

07.25.2017

Kezar Life Sciences Announces Successful Completion of Phase 1a S...

05.25.2017

Liquidia Technologies Announces Positive Phase 1 Data for LIQ865,...

05.24.2017

New Pappas Capital Fund Makes First Investment

05.24.2017

OrphoMed Secures $39 Million Series A Financing Round

05.11.2017

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Pr...

03.27.2017

TESARO Announces U.S. FDA Approval of ZEJULA™ (niraparib) ...

03.07.2017

Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliv...

03.01.2017

Lilly Completes Acquisition of CoLucid Pharmaceuticals

02.03.2017

Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phas...

01.18.2017

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To...

10.17.2016

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data...

09.28.2016

Athersys Receives FDA Agreement Under Special Protocol Assessment...

09.06.2016

CoLucid Pharmaceuticals Announces Achievement of Both Primary and...

08.18.2016

Rotation Medical Secures $12 Million in Series B Extension Financing

07.18.2016

IlluminOss Medical Completes Enrollment for U.S. Clinical Trial U...

07.06.2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreemen...

06.10.2016

Merck to Acquire Afferent Pharmaceuticals

06.07.2016

CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMU...

05.19.2016

CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pi...

05.04.2016

Envisia Therapeutics Announces Positive Three-Month Interim Resul...

04.26.2016

Afferent Pharmaceuticals Announces Presentations of Chronic Cough...

03.23.2016

Envisia Therapeutics Secures $16.5 Million In Additional Series A...

03.02.2016

Syndax Announces Pricing of Initial Public Offering

03.01.2016

CoLucid Pharmaceuticals Announces Special Protocol Agreement for ...

02.29.2016

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Rang...

02.23.2016

CoLucid Pharmaceuticals Announces Confirmatory Support for Non-va...

02.17.2016

One-Year Results From Phase 2 Stroke Study of MultiStem® Cell The...

01.13.2016

Envisia Therapeutics Announces First Patient Dosed in Second Coho...

01.08.2016

Healios and Athersys Enter Into Regenerative Medicine Partnership...

01.05.2016

Afferent Pharmaceuticals named one of “The Hottest Startups...

01.04.2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collab...

12.08.2015

Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phas...

12.01.2015

Syndax Announces Initiation Of Entinostat Clinical Program In Jap...

11.30.2015

CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update

11.19.2015

Afferent Pharmaceuticals Expands Executive Leadership Team With A...

11.11.2015

Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF...

11.10.2015

Thrasos Strengthens Composition of Matter Coverage on THR-184 wit...

10.27.2015

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D....

10.09.2015

ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost ...

10.09.2015

Chimerix Presents Preliminary Data on Brincidofovir in Liver Tran...

10.09.2015

CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term...

10.09.2015

Medtronic TYRX(TM) Neuro Absorbable Antibacterial Envelope now Av...

10.08.2015

Wake Forest Baptist Medical Center Creates $15 Million Program to...

10.02.2015

Anthera Announces Initiation of the SOLUTION Clinical Study of Or...

09.30.2015

Liquidia Technologies and GlaxoSmithKline Advance Existing Collab...

09.28.2015

Afferent Pharmaceuticals Announces Positive Results in Phase 2b C...

09.17.2015

CardioDx Expands Patient Access to the Corus(R) CAD Test Through ...

09.02.2015

TESARO Announces U.S. FDA Approval of VARUBI™ (rolapitant)...

09.02.2015

Chimerix and BARDA Announce Continued Partnership in the Developm...

08.26.2015

SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAP...

08.24.2015

SYNDAX RAISES $80 MILLION IN SERIES C FINANCING

08.18.2015

Rotation Medical Featured in Local News Story

07.21.2015

IlluminOss Medical Appoints Clive Ridgwell as Vice President of S...

07.14.2015

Liquidia Technologies Names Robert A. Lippe Chief Operations Officer

07.08.2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study fo...

07.08.2015

Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Cro...

06.15.2015

Milestone Pharmaceuticals Closes US$17 Million Series B Financing...

05.06.2015

CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering

05.04.2015

Envisia Therapeutics to Present at ARVO 2015 Annual Meeting

04.29.2015

IlluminOss Medical Appoints Amy Orlick Berman as Vice President o...

04.28.2015

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Piv...

04.14.2015

Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer

03.31.2015

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 ...

03.31.2015

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluati...

03.24.2015

IlluminOss Medical Announces the Enrollment of First Patient in P...

03.19.2015

A drug that could raise IQ – Balance Therapeutics raises $1...

03.19.2015

Anthera Announces $3 Million Research Award from Cystic Fibrosis ...

03.16.2015

Anthera Pharmaceuticals Announces Completion of Interim Analysis ...

03.03.2015

IlluminOss Medical Announces the Enrollment of First Patient in E...

03.02.2015

Athersys and Chugai Enter License Agreement and Collaboration to ...

02.08.2015

Triangle Global Health Consortium Recognizes Chimerix with 2015 C...

01.27.2015

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515...

01.22.2015

Athersys and Cell Therapy Catapult Announce Grant to Support Clin...

01.13.2015

CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C P...

01.12.2015

Chimerix Receives Notice of Allowance for Brincidofovir Compositi...

01.12.2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phas...

01.07.2015

Ultragenyx Announces License of Intellectual Property Related to ...

01.07.2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocet...

01.07.2015

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreem...

01.06.2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored...

01.06.2015

Ultragenyx Initiates New Development Program Studying KRN23 for t...

01.05.2015

New Clinical Trial Will Evaluate Antibacterial Envelope in Cardia...

12.29.2014

Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cel...

12.23.2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of P...

12.18.2014

CardioDx Raises $35 Million in Equity Financing

12.18.2014

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collab...

12.15.2014

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Z...

12.15.2014

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant H...

12.10.2014

IlluminOss Medical Caps off Flagship Year with Addition of New Pa...

11.25.2014

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cou...

11.24.2014

Milestone Announces Positive Phase 1 Data for MSP-2017; Supports ...

11.18.2014

IlluminOss Medical Announces Conditional FDA Approval for Clinica...

11.13.2014

Chimerix’s Brincidofovir Selected for Use in Ebola Clinical...

11.08.2014

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ...

11.06.2014

Michael Grey Joins Mirati Therapeutics Board of Directors

10.30.2014

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the T...

10.28.2014

Chimerix hammers out an emergency PhII Ebola study for antiviral

10.27.2014

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for t...

10.20.2014

CardioDx Announces Results of Study Demonstrating the Benefits of...

09.25.2014

LabCorp Announces Agreement to Acquire LipoScience

09.22.2014

Medtronic Announces CE Mark and European Launch of TYRX(TM) Absor...

09.16.2014

Thrasos Announces Successful Formal Interim Analysis and Clinical...

09.15.2014

Rotation Medical Initiates Post-Market Clinical Study Of Rotator ...

09.15.2014

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 ...

09.08.2014

TESARO Announces Submission of Rolapitant New Drug Application (N...

08.11.2014

Mirati Therapeutics Receives Orphan Designation from U.S. Food &#...

08.05.2014

Ultragenyx Announces License of Intellectual Property for the Tre...

07.31.2014

New Data on Chimerix’s Brincidofovir Supports Safety and An...

07.30.2014

MedStar Union Memorial Hospital is First Hospital in Country to O...

07.14.2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (lipro...

07.07.2014

CardioDx Announces Aetna and Coventry Health Coverage for Corus® ...

07.01.2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for P...

07.01.2014

Rotation Medical Completes $27.2 Million Series B Financing

06.24.2014

Venture Partner Mike Grey named EY Entrepreneur Of The Year San D...

06.24.2014

Ultragenyx Announces Results from Phase 1/2 Study of KRN23 in X-l...

06.17.2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Fo...

06.03.2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents ...

05.14.2014

Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extensi...

05.12.2014

Shire adds to rare disease portfolio with acquisition of Lumena P...

05.12.2014

TESARO Announces Successful Achievement of Primary and All Second...

05.09.2014

Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 ...

05.06.2014

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA o...

05.05.2014

New Study Results Further Reinforce that the Corus® CAD Test Help...

04.30.2014

Ultragenyx Announces Positive Data From Phase 2 Study of Sialic A...

04.23.2014

MUSC Foundation for Research Development welcomes Art Pappas to b...

04.17.2014

IlluminOss receives new patents for bone stabilization system

03.27.2014

Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Rec...

03.11.2014

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

03.11.2014

Ultragenyx Announces First Patient Enrolled in Phase 2 Study of T...

03.10.2014

Study Finds the Corus® CAD Gene Expression Blood Test Influenced ...

02.24.2014

Marina Biotech Announces $6 MM Convertible Preferred Stock Financ...

02.12.2014

Ultragenyx Announces Presentation of Data From a Single Patient T...

02.11.2014

Ultragenyx Announces Initiation of Phase 2 Study for Patients wi...

02.06.2014

Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board...

02.06.2014

IlluminOss Medical introduces bone stabilization system in Spain,...

02.05.2014

Ultragenyx Announces Closing of Initial Public Offering and Exerc...

01.30.2014

Ultragenyx Announces Pricing of Initial Public Offering

01.22.2014

LipoScience Announces Appointment of Howard Doran as President an...

01.08.2014

Pappas Ventures Promotes Scott Weiner to Partner

01.06.2014

Medtronic Announces Acquisition of TYRX, INC., Developer of Solut...

12.20.2013

Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Ex...

12.17.2013

Ultragenyx Investigational New Drug Application for Triheptanoin ...

12.10.2013

Pappas Ventures Names Franz B. Humer as Venture Partner and Senio...

12.04.2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord N...

11.18.2013

Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug ...

11.12.2013

Envisia Therapeutics Debuts with $25 Million Series A Financing

11.05.2013

Inhibition of ASBT Improves Liver Function in an Animal Model of ...

10.29.2013

Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LU...

10.22.2013

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Di...

10.10.2013

New Data Highlight Value of Corus® CAD in Reducing Unnecessary Ca...

10.06.2013

Ultragenyx Announces the Presentation of Data from a Single Dose ...

10.02.2013

Chimerix Announces Publication of Positive Phase 2 Results of Bri...

09.26.2013

Ultragenyx Announces Three Abstracts Accepted for Poster Presenta...

09.26.2013

Lumena Pharmaceuticals Receives Orphan Drug Designation from US F...

09.26.2013

Lumena Pharmaceuticals Launches Global Clinical Program to Evalua...

09.24.2013

Ultragenyx selected as 2013 Fierce 15 Company

09.16.2013

Ultragenyx Announces Positive Data from Retrospective Study of UX...

09.11.2013

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results

09.09.2013

Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX00...

09.04.2013

LipoScience Announces New Data Supporting High-Density Lipoprotei...

09.03.2013

Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Deve...

08.27.2013

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing f...

08.14.2013

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus S...

08.14.2013

Ultragenyx Receives Approval of Clinical Trial Application (CTA) ...

08.12.2013

TYRX Announces First U.S. Implantation of AIGISRx® R Fully Biores...

08.05.2013

Ultragenyx Initiates New Development Program Studying Triheptanoi...

07.31.2013

LipoScience Research Sheds Light On Novel Markers Via Nuclear Mag...

07.23.2013

TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Pati...

07.23.2013

TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Enve...

07.23.2013

Stem cell therapy for transplants developed by Athersys Inc. may ...

07.15.2013

Chimerix CEO: Public market is critical to financing biotech R�...

07.11.2013

Ultragenyx Gains Worldwide Rights for Triheptanoin (UX007)

07.09.2013

TYRX Receives FDA Clearance for Fully Resorbable AIGISRx® R Antib...

07.03.2013

Ultragenyx Announces a Positive Signal in Interim Data from Phase...

06.28.2013

Mirati Therapeutics and MethylGene Announce Completion of Plan of...

06.28.2013

TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) ...

06.26.2013

Zero Infections in High-Risk Cardiac Device Replacements Reported...

06.24.2013

Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study ...

06.19.2013

Repurposing a cholesterol drug candidate for cholestatic liver di...

05.21.2013

Liquidia Technologies Announces Extension of Collaboration with P...

05.21.2013

Scott will provide his perspective on the investment outlook for ...

05.15.2013

Art Pappas Elected to NVCA Board of Directors

05.15.2013

Ultragenyx Advances Clinical Development of UX003 for the Treatme...

05.10.2013

Independent Study Shows Significant Decline in Cardiac Device Inf...

05.02.2013

Nanotechnology firm Liquidia plans new ophthalmology company

05.01.2013

Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Se...

05.01.2013

Ultragenyx Press Release: Ultragenyx Appoints Eric Yuen, MD as Ch...

04.22.2013

Jayson Punwani will moderate a discussion on Impact Investing at ...

04.22.2013

Scott Weiner will moderate a discussion on the current IPO market...

04.15.2013

TyRx Press Release – TYRX® Announces First EverImplantation...

04.15.2013

TYRX® Announces First EverImplantation of AIGISRx® R Fully Resorb...

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

UltraGenyx Press Release – Ultragenyx Initiates Novel Disea...

03.21.2013

Art Pappas will moderate the panel “Driving Innovation from...

03.20.2013

Art Pappas will join the panel, “The Research, Funding and ...

03.19.2013

Art Pappas joins a panel at the 2013 BIO International Convention...

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.20.2013

Ernest Mario named Chairman of Chimerix

02.20.2013

Ernest Mario named Chairman of Chimerix

02.11.2013

Art Pappas will join the panel, “How the Other Half Lives: ...

01.30.2013

LipoScience Press Release – LipoScience Announces Closing o...

01.30.2013

LipoScience Announces Closing of Initial Public Offering

01.25.2013

LipoScience Press Release – LipoScience Prices Initial Publ...

01.10.2013

Ultragenyx Press Release – Ultragenyx Announces In-Licensin...

01.10.2013

Ultragenyx Announces In-Licensing of Clinical-Stage Product Trihe...

01.10.2013

LipoScience Sets IPO Term

01.09.2013

LIPOSCIENCE COLLABORATES WITH A LEADING ACADEMIC MEDICAL CENTER T...

12.20.2012

Ultragenyx Press Release – Raises $75 Million in Oversubscr...

12.20.2012

Ultragenyx Press Release – Ultragenyx Raises $75 Million in...

12.20.2012

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.12.2012

Chimerix Press Release – Chimerix Appoints Michelle Berrey ...

11.12.2012

Chimerix Appoints Michelle Berrey Chief Medical Officer

10.29.2012

Jayson Punwani will moderate a panel at the 2nd annual Kenan-Flag...

10.25.2012

Thrasos Press Release – Thrasos Secures $35 Million to Fund...

10.25.2012

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Prog...

10.04.2012

TyRx Press Release – TYRX(R) Receives Health Canada Approval

10.04.2012

TYRX(R) Receives Health Canada Approval

10.02.2012

TyRx Press Release – FierceMedicalDevices Names TYRX® as on...

10.02.2012

FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medica...

10.02.2012

CardioDx Press Release – CardioDx Honored as One of FierceM...

10.02.2012

CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most P...

10.02.2012

Two Pappas Ventures’ Portfolio companies make FierceMedical...

09.27.2012

IlluminOss Press Release – IlluminOss Medical Secures $28 M...

09.27.2012

IlluminOss Medical Secures $28 Million Series C Financing for Min...

09.20.2012

Mike Grey will join a panel to discuss the future of venture capi...

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.14.2012

TyRx Press Release – TYRX(R) Receives New Product Innovatio...

09.14.2012

TYRX(R) Receives New Product Innovation Award

09.05.2012

LipoScience Press Release – LipoScience Receives FDA Cleara...

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

08.27.2012

CardioDx Press Release – CardioDx Completes $58 Million Equ...

08.27.2012

CardioDx Completes $58 Million Equity Financing

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.20.2012

TyRx Press Release – Over 50% of Hospital CFOs Plan to Adop...

08.20.2012

Art Pappas joins a Venture Capital Panel at Mid-Atlantic Bio on S...

08.14.2012

Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012...

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

07.31.2012

Scott Weiner will join a panel discussion around perspectives on ...

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Art Pappas makes TBJ “Triangle’s Most Influential Bus...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.25.2012

MethylGene announces encouraging data from Phase I tumor study

06.25.2012

MethylGene Announces Encouraging Data from Phase 1 Tumor Study

06.20.2012

Liquidia Announces Product Development Collaboration with GSK

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Technologies signs lucrative deal with GSK

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.05.2012

CED Selects Officers and Board of Directors Members

05.23.2012

Mike Grey will join a discussion panel entitled “Are we Hea...

05.16.2012

Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Dir...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Achillion gets FDA incentives for hepatitis C drug

05.15.2012

Achillion gets FDA Incentives for Hepatitis C Drug

05.14.2012

Scott will join a panel discussion focusing on raising US venture...

05.03.2012

Liquidia Founder Dr. Joseph DeSimone Elected into National Academ...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.23.2012

Ultragenyx Relocates Company Headquarters to Support Operational ...

04.19.2012

Syndax Pharmaceuticals Inc. Appoints Arlene Morris as CEO

04.06.2012

Liquidia figuring out how to ‘unleash’ technology

04.06.2012

Orphan Diseases and the Future of BioPharma, the Focus of the 201...

04.06.2012

Syndax Pharmaceuticals Inc. Appoints Arthur M. Pappas to Board of...

04.03.2012

Liquidia CEO to Participate in Biotech Panel to Explore “How to C...

04.02.2012

Big business appeal of nanotechnology on display in Durham

04.02.2012

Big Business Appeal of Nanotechnology on Display in Durham

04.02.2012

What venture capitalists look for in personalized medicine invest...

03.28.2012

Turner will provide his perspective on adopting personalized medi...

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.26.2012

Tesaro promises rapid progress with cancer drugs in $86M IPO

03.26.2012

TESARO promises rapid progress with cancer drugs in $86M IPO

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.19.2012

Art will provide featured remarks to the Harvard Business School ...

03.19.2012

Art Pappas will participate on a panel to discuss exit strategies...

03.15.2012

Hagan Bill Could Speed Approval Process for Drugs

03.14.2012

Marina, ProNAi in cancer deal

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.06.2012

Eric Linsley offers perspective on personalized medicine’s develo...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

02.29.2012

Art Pappas will moderate and lead a discussion entitled “Ar...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.21.2012

Eric Linsley will lead a discussion on “Partnering and Lice...

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.08.2012

Scott Weiner will present and sit on a panel at the IN3 Medical D...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.02.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

02.01.2012

A Path Forward for the FDA

02.01.2012

A Path Forward for the FDA

02.01.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

01.31.2012

Eric Linsley speaks on CED Life Science

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.23.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

PRINTed Nanoparticles Delivery Multiple Punches to Treat Prostate...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Art Pappas speaks on life sciences innovation at Biotech Showcase...

01.09.2012

FDA New Drug Approvals in 2011 Outpace Recent Past

01.04.2012

Achillion hepatitis drug gets faster FDA review

01.04.2012

ACH-1625 Receives Fast Track Designation From the FDA for the Tre...

Upcoming Events.

Events Past Events

08.27.2020

Kyle Rasbach will serve on a panel at the World Orphan Drug Congress USA 2020

Kyle Rasbach will serve on the panel “Evaluating investment…

Location

(virtual)

pappas_capitalFollow

pappas_capital @pappas_capital·

Pappas Capital portfolio company Ribometrix announces collaboration with Genentech to discover and develop RNA-targeted small molecule therapeutics. https://www.businesswire.com/news/home/20210106005073/en/Ribometrix-Announces-Collaboration-with-Genentech-to-Discover-and-Develop-RNA-Targeted-Small-Molecule-Therapeutics#.X_c3grAI9pA.twitter

Reply on Twitter 1347219659427340295 Retweet on Twitter 1347219659427340295 Like on Twitter 1347219659427340295

pappas_capital @pappas_capital·

Aura Biosciences Appoints David Johnson to Its Board of Directors | Business Wire https://www.businesswire.com/news/home/20210105005282/en/Aura-Biosciences-Appoints-David-Johnson-to-Its-Board-of-Directors#.X_YnODtg6cw.twitter

Reply on Twitter 1346927145692573700 Retweet on Twitter 13469271456925737001 Like on Twitter 13469271456925737003

pappas_capital @pappas_capital·

Pappas Capital portfolio company BioAtla announces pricing of initial public offering. https://prn.to/389zhdt

Reply on Twitter 1339200705106731010 Retweet on Twitter 13392007051067310101 Like on Twitter 13392007051067310102

pappas_capital @pappas_capital·

Pappas Capital portfolio company 4D Molecular Therapeutics announces upsized pricing of initial public offering. https://www.globenewswire.com/news-release/2020/12/11/2143511/0/en/4D-Molecular-Therapeutics-Announces-Upsized-Pricing-of-Initial-Public-Offering.html#.X9OexSOalYs.twitter

Reply on Twitter 1337434897795981312 Retweet on Twitter 1337434897795981312 Like on Twitter 13374348977959813122

VelosBio to be Acquired by Merck…

Upcoming Events.